These algorithms utilize readily available clinical parameters (such as ALT, Body mass index, and AST) to predict the presence or severity of NAFLD, offering advantages in terms of cost, accessibility, and standardization. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.